奥沙利铂联合EPCs-hαIFN抑制肝细胞癌实验研究

The efficacy of sequenced cytotoxinic Oxaliplatin and EPCs delivering the genes of hαIFN in hepotocellular carcinoma therapy

目的:研究序贯给予奥沙利铂及携带α干扰素基因的内皮祖细胞(EPCs-hαIFN)对肝细胞癌的抑制效果。方法:体外观察Hep G-2肝癌细胞在加入奥沙利铂(L-OHP,5μmol/L,第1天)后,再加入hαIFN(500IU/ml,第2~4天)观察对肿瘤细胞的抑制作用;荷瘤裸鼠在给予细胞毒性药物L-OHP(5mg/kg IP,1周2次)后,给予EPCs-hαIFN(1×106IV,每周1次),观察肿瘤的生长情况和裸鼠生存期。结果:在体外,肿瘤细胞中加入L-OHP后,再加入hαIFN可以进一步抑制肿瘤细胞的生长;荷瘤裸鼠在给予L-OHP后,再给予EPCs-hαIFN可以进一步减缓肿瘤的生长[肿瘤平均体积:空白对照组为(2 100.28±340.40)mm^3,单用LOHP组为(822.94±221.14)mm^3,联合EPCs-hαIFN组为(334.85±154.11)mm^3,P<0.05]。联合EPCshαIFN可以延长荷瘤裸鼠的生存期(中位生存期:空白对照组为35.3天,95%可信区间为32.8~36.9天;单用L-OHP组为38.7天,95%可信区间为36.1~40.8天;联合EPCs-hαIFN组为43.5天,95%可信区间为42.1~45.7天,P<0.01)。结论:给予奥沙利铂联合EPCs-hαIFN,可以更好地抑制肝细胞癌生长,延长荷瘤动物的生存期。

Objective：To observe the the efficacy of sequentially giving of Oxaliplatin and EPCs -hαIFN in hepa-tocellular carcinoma therapy.Methods：In vitro,MTT was used to observe the inhabitation of hαIFN（500IU /ml,day 2~4）to HepG -2 cancer cells after being given Oxaliplatin（L -OHP,5μmol/L,day 1）.Nude mice with HepG -2 xenograft tumor were used to investigate the effect of EPCs -hαIFN of antitumor and prolongation of survival,after the mice were treated by L -OHP.Results：In vitro,hαIFN could inhibit the growth of cancer cells after being given of L-OHP（5mg/kg IP,twice a week）.After given L -OHP,the nude mice with HepG -2 xenograft tumor were given EPCs -hαIFN（1 ＆#215;106 IV,once a week）,EPCs -hαIFN could inhibit the growth of tumors[mean volumne of the tumors：Control group,（2 100.28 ±340.40）mm3;L -OHP group,（822.94 ±221.14）mm3;L -OHP ＋ EPCs -hαIFN group,（334.85 ±154.11）mm3 ,P〈0.05].The survival of mice were prolonged when been given EPCs -hαIFN（media survival：Control group,35.3 days,95%CI 32.8 ~36.9 days;L -OHP group,38.7 days,95%CI 36.1~40.8 days;L -OHP ＋EPCs -hαIFN group,43.5 days,95%CI 42.1 ~45.7 days,P〈0.01）.Conclusion：EPCs-hαIFN combined L -OHP could inhibit the growth of the tumors and prolonged the survival of the mice.